RxDoctor Payments Data

Anisbel Hornia Silva

General Practice · South Gate, CANPI 1740763036

Payments from drug & device makers

$3,623in general payments, 2019–2025

Across 176 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$527
  • Alkermes, Inc.$484
  • AbbVie$411
  • Axsome Therapeutics, Inc.$325
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$303
  • Neurocrine Biosciences, Inc.$234
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,58899%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,623 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$27,111
Medicare patients
92
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide48$74,687
JardianceEmpagliflozin80$66,039
OzempicSemaglutide56$55,130
JanuviaSitagliptin Phosphate52$34,171
RexultiBrexpiprazole16$25,546
Tresiba Flextouch U-200Insulin Degludec32$19,108
EntrestoSacubitril/Valsartan20$18,433
Diclofenac Sodium103$14,320
EliquisApixaban13$13,891
MounjaroTirzepatide12$13,527
FarxigaDapagliflozin Propanediol13$13,057
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$6,474
MyrbetriqMirabegron13$6,029
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$5,557
Repatha SureclickEvolocumab11$5,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$109$88,21560 claims
Novo NordiskOzempic$213$55,13056 claims
Otsuka America Pharmaceutical, Inc.Rexulti$527$25,54616 claims
NovartisEntresto$20$18,43320 claims
PfizerEliquis$17$13,89113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in South Gate

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →